CXCL9 and metastatic malignant neoplasm: Of the GPCRs and their agonists that showed clear contrast in their Spearman correlation values comparing the high and low PREX1 expression groups, we found a known chemokine-GPCR pair, CXCL9-CXCR3, already described as relevant in metastatic cancer progression (54).